Rosing J, Hoekema L, Nicolaes G A, Thomassen M C, Hemker H C, Varadi K, Schwarz H P, Tans G
Cardiovascular Research Institute Maastricht, University of Limburg, The Netherlands.
J Biol Chem. 1995 Nov 17;270(46):27852-8. doi: 10.1074/jbc.270.46.27852.
Inactivation of membrane-bound factor Va by activated protein C (APC) proceeds via a biphasic reaction that consists of a rapid and a slow phase, which are associated with cleavages at Arg506 and Arg306 of the heavy chain of factor Va, respectively. We have investigated the effects of protein S and factor Xa on APC-catalyzed factor Va inactivation. Protein S accelerates factor Va inactivation by selectively promoting the slow cleavage at Arg306 (20-fold). Factor Xa protects factor Va from inactivation by APC by selectively blocking cleavage at Arg506. Inactivation of factor VaR506Q, which was isolated from the plasma of a homozygous APC-resistant patient and which lacks the Arg506 cleavage site, was also stimulated by protein S but was not affected by factor Xa. This confirms that the target sites of protein S and factor Xa involve Arg306 and Arg506, respectively. Factor Xa completely blocked APC-catalyzed cleavage at Arg506 in normal factor Va (1 nM) with a half-maximal effect (K1/2Xa) at 1.9 nM factor Xa. Expression of cofactor activity of factor Va in prothrombin activation required much lower factor Xa concentrations (K1/2Xa = 0.08 nM). When the ability of factor Xa to protect factor Va from inactivation by APC was determined at low factor Va concentrations during prothrombin activation much lower amounts of factor Xa were required (K1/2Xa = 0.03 nM). This indicates 1) that factor Va is optimally protected from inactivation by APC by incorporation into the prothrombinase complex during ongoing prothrombin activation, and 2) that the formation of a catalytically active prothrombinase complex and protection of factor Va from inactivation by APC likely involves the same interaction of factor Xa with factor Va. In accordance with the proposed mechanisms of action of protein S and factor Xa, we observed that the large differences between the rates of APC-catalyzed inactivation of normal factor Va and factor VaR506Q were almost annihilated in the presence of factor Xa and protein S. This observation may explain why, in the absence of other risk factors, APC resistance only results in a weak prothrombotic condition.
活化蛋白C(APC)介导的膜结合因子Va失活通过双相反应进行,该反应由快速相和缓慢相组成,分别与因子Va重链的Arg506和Arg306处的裂解有关。我们研究了蛋白S和因子Xa对APC催化的因子Va失活的影响。蛋白S通过选择性促进Arg306处的缓慢裂解(20倍)来加速因子Va失活。因子Xa通过选择性阻断Arg506处的裂解来保护因子Va不被APC失活。从纯合APC抵抗患者血浆中分离出的缺乏Arg506裂解位点的因子VaR506Q的失活也受到蛋白S的刺激,但不受因子Xa的影响。这证实了蛋白S和因子Xa的靶位点分别涉及Arg306和Arg506。因子Xa在1.9 nM因子Xa时以半数最大效应(K1/2Xa)完全阻断正常因子Va(1 nM)中APC催化的Arg506处的裂解。在凝血酶原激活中因子Va辅因子活性的表达需要低得多的因子Xa浓度(K1/2Xa = 0.08 nM)。当在凝血酶原激活过程中低因子Va浓度下测定因子Xa保护因子Va不被APC失活的能力时,所需的因子Xa量要低得多(K1/2Xa = 0.03 nM)。这表明:1)在正在进行的凝血酶原激活过程中,通过掺入凝血酶原酶复合物,因子Va能得到最佳保护以免被APC失活;2)催化活性凝血酶原酶复合物的形成以及因子Va免受APC失活的保护可能涉及因子Xa与因子Va的相同相互作用。根据提出的蛋白S和因子Xa的作用机制,我们观察到在因子Xa和蛋白S存在的情况下,APC催化的正常因子Va和因子VaR506Q失活速率之间的巨大差异几乎消失。这一观察结果可能解释了为什么在没有其他危险因素的情况下,APC抵抗仅导致轻度的血栓前状态。